Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.

与普通人群相比，癌症患者的 SARS-CoV-2 感染负担、疾病严重程度、并发症和死亡率更高。 SARS-CoV-2 mRNA 疫苗对普通人群非常有效；然而，关于它们对癌症患者的疗效的数据很少。通过前瞻性队列研究，我们评估了美国和欧洲癌症患者自 1 月起第一剂和第二剂 BNT162b2 和 mRNA-1273 SARS-CoV-2 疫苗后的血清转化率和抗 SARS-CoV-2 刺突蛋白抗体滴度到 2021 年 4 月。在 131 名患者中，大多数 (94%) 在接受两剂疫苗后实现了血清转化。血液恶性肿瘤患者的血清转化率和抗体滴度显着低于实体瘤患者。接种前6个月内有抗CD-20抗体史的患者均未出现抗体反应。临床监测或内分泌治疗组的抗体滴度最高，细胞毒化疗或单克隆抗体组的抗体滴度最低。